Related Experiment Video

Updated: Jun 23, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure

Mikkel Andreassen1, Caroline Kistorp, Ilan Raymond

  • 1Department of Endocrinology J, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark. andreassenmikkel@hotmail.com

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|April 29, 2009
PubMed

Insights

Insulin-like growth factor I (IGF-I) levels were similar in patients with congestive heart failure (CHF) and healthy individuals. IGF-I did not impact cardiac function or predict mortality risk in CHF patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Insulin-like growth factor I (IGF-I) is an anabolic hormone with potential roles in cardiac function.
  • Reduced IGF-I levels have been hypothesized to contribute to the progression of congestive heart failure (CHF).

Purpose of the Study:

  • To compare plasma IGF-I levels between CHF patients and healthy controls.
  • To investigate the association between baseline IGF-I levels, cardiac contractility, and prognosis in CHF patients, including all-cause mortality and hospital admissions for worsening CHF.

Main Methods:

  • A prospective study involving 194 CHF outpatients and 169 matched controls.
  • Echocardiographic examinations were performed at baseline for all participants.
  • Patients were followed for a median of 30 months to assess outcomes.

Main Results:

  • No significant difference in plasma IGF-I levels was observed between CHF patients and controls.
  • IGF-I levels did not correlate with left ventricular ejection fraction (LVEF) or N-terminal B-Type natriuretic peptide (NT-proBNP) levels.
  • After adjusting for cardiovascular risk factors, IGF-I levels did not predict overall mortality risk or hospital admission rates for CHF exacerbation.

Conclusions:

  • Plasma IGF-I levels are not reduced in patients with CHF compared to healthy individuals.
  • Baseline IGF-I levels do not appear to influence cardiac status or long-term prognosis in patients with CHF.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...